

### **Amendments to the Claims**

The listing of claims will replace all prior versions, and listing of claims in the application.

#### **Listing of Claims**

1-126. (Canceled).

127. (Previously presented) A method of treating or preventing an affective disorder which comprises administering to a patient in need of such treatment or prevention a therapeutically or prophylactically effective amount of a bupropion metabolite, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof, wherein the bupropion metabolite, or pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof, is adjunctively administered with a therapeutically or prophylactically effective amount of a second pharmacologically active compound.

128. (Previously presented) The method of claim 127, wherein the bupropion metabolite is optically pure (S,S)-2-(3-chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morphine-~~3-N-oxide~~ morpholinol, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof.

129. (Previously presented) The method of claim 127, wherein the affective disorder is alcohol addiction, an anxiety disorder, attention deficit disorder, attention deficit disorder with hyperactivity, attention deficit/hyperactivity disorder, a bipolar or manic condition, bulimia, chronic fatigue syndrome, cocaine addiction, depression, narcolepsy, nicotine addiction, obesity, premenstrual syndrome, seasonal affective disorder, or weight-gain.

130. (Previously presented) The method of claim 128, wherein the affective disorder is alcohol addiction, an anxiety disorder, attention deficit disorder, attention deficit disorder with hyperactivity, attention deficit/hyperactivity disorder, a bipolar or manic condition, bulimia, chronic fatigue syndrome, cocaine addiction, depression, narcolepsy, nicotine addiction, obesity, premenstrual syndrome, seasonal affective disorder, or weight-gain.

131. (Previously presented) The method of claim 127, wherein the second pharmacologically active compound is a selective serotonin reuptake inhibitor, a 5-HT<sub>3</sub> inhibitor, or nicotine.

132. (Previously presented) The method of claim 128, wherein the second pharmacologically active compound is a selective serotonin reuptake inhibitor, a 5-HT<sub>3</sub> inhibitor, or nicotine.